


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below:

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. ARYX-102XC4Z
Serial No. 10/697,683

January 19, 2004

David Saliwanchik

David R. Saliwanchik, Patent Attorney



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit :
Applicant(s) : Pascal Druzgala, Peter G. Milner
Serial No. : 10/697,683
Conf. No. :
Filed : October 29, 2003
For : Novel Enantiomeric Compounds for Treatment of Cardiac Arrhythmias
And Methods of Use

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the reference listed on the attached form PTO-1449 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited document is enclosed.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David Saliwanchik

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRS/la

Attachments: Form PTO-1449 and copies of references listed therein



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/697,683	
			Filing Date	October 29, 2003	
			First Named Inventor	Pascal Druzgala	
			Art Unit		
			Examiner Name		
Sheet	1	of	2	Attorney Docket Number	ARYX-102XC4Z

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-4,931,464	06-05-1990	Grover <i>et al.</i>	
	U2	US-4,962,095	10-09-1990	Grover <i>et al.</i>	
	U3	US-5,175,187	12-29-1992	Baligadoo	
	U4	US-5,364,880	11-15-1994	Druzgala	
	U5	US-5,440,054	08-08-1995	Druzgala	
	U6	US-5,849,788	12-15-1998	Druzgala	
	U7	US-6,362,223 B1	03-26-2002	Druzgala <i>et al.</i>	
	U8	US-6,372,783	04-16-2002	Druzgala <i>et al.</i>	
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 94/29289 A	12-22-1994	Advanced Therapies, Inc.		
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/697,683
Filing Date	April 15, 2002
First Named Inventor	Pascal Druzgala
Group Art Unit	
Examiner Name	
Attorney Docket Number	ARYX-102XC4Z

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Cairns, John A., Stuart J. Connolly, Robin Roberts <i>et al.</i> (March 8, 1997) "Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT" <i>Lancet</i> 349:675-682.	
	R2	Charlier <i>et al.</i> (1969) <i>Cardiologia</i> 54:82	
	R3	Connolly, S., J. Cairns, M. Gent <i>et al.</i> (November 15, 1997) "Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials" <i>Lancet</i> 350:1417-1424.	
	R4	Juhasz, A., N. Bodor (2000) "Cardiovascular Studies on Different Classes of Soft Drugs" <i>Pharmazie</i> 55(3):228-238 (abstract only)	
	R5	Julian, D.G., A.J. Camm, G. Frangin <i>et al.</i> (March 8, 1997) "Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT" <i>Lancet</i> :349:667-674.	
	R6	Kerr, Charles R. Mauricio B. Osenbaum, Pablo A. Chiale (1996) "Amiodarone" <i>In: Cardiovascular Drug Therapy</i> , Editor: Messerli, F.H.W.B. Saunders Co., 2 nd Edition, Chapter 138, pages 1247-1264.	
	R7	Kowey, Peter R., Joseph H. Levine, John M. Herre <i>et al.</i> (December 1, 1995) "Randomized, Double-Blind Comparison of Intravenous Amiodarone and Bretylium in the Treatment of Patients with Recurrent, Hemodynamically Destabilizing Ventricular Tachycardia or Fibrillation" <i>Circulation</i> 92(11):3255-3263.	
	R8	Naccarelli, Gerald, Robert L. Rinkenberger, Anne H. Dougherty, Ruth A. Giebel (Nov/Dec. 1985) "Evaluations of New Drugs: Amiodarone: Pharmacology and Antiarrhythmic and Adverse Effects" <i>Pharmacotherapy</i> 5(6):298-313.	
	R9	Rosenbaum, Mauricio B., Pablo A. Chiale, M. susana Halpern <i>et al.</i> (December 1976) "Clinical Efficacy of Amiodarone as an Antiarrhythmic Agent" <i>The American Journal of Cardiology</i> 38:934-944.	
	R10	Rosenbaum, Mauricio, Pablo A. chiale, David Ryba, Marcelo V. elizari (August 1974) "Control of Tachyarrhythmias Associated with Wolff-Parkinson-White Syndrome by Amiodarone Hydrochloride" <i>The American Journal of Cardiology</i> 34:215-223.	
	R11	Singh, B.N. and E.M. Vaughan Williams (1970) "The effect of amiodarone, a new anti-anginal drug, on cardiac muscle" <i>Br. J. Pharmacol</i> 39:657-667	
	R12	Vrobel, Thomas R., Paul E. Miller, Nelson D. Mostow, Louis Rakita (May/June 1989) "A General Overview of Amiodarone Toxicity: Its Prevention, Detection, and Management" <i>Progress in Cardiovascular Diseases</i> 31(6):393-426.	
	R13		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.